Pharmaceutical company AstraZeneca (AZNCF) said it had agreed to sell its small molecule antibiotics business to Pfizer (PFE) in a deal that could reach more than $1.5 billion.
The portfolio includes approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development, it said.
Pfizer will pay $550 million upon completion and a further unconditional $175 million in January 2019, AstraZeneca said, plus up to $250 million in milestones, up to $600 million in sales-related payments and recurring, double-digit royalties on future sales of Zavicefta and ATM-AVI in certain markets.
For more on Pfizer, watch Fortune’s video:
The British company said the agreement did not impact its financial guidance for 2016.